<DOC>
	<DOCNO>NCT02508753</DOCNO>
	<brief_summary>The purpose study look possible side effect two different dos CXA-101/tazobactam , low dose high dose , participant 's heart .</brief_summary>
	<brief_title>Safety Study Designed Study Effects Two Different Doses CXA-101/Tazobactam , Low Dose High Dose , QT/QTc Intervals Healthy Subjects</brief_title>
	<detailed_description>Some drug effect cardiovascular system ( heart blood vessel ) include QT interval . The QT interval time contraction relaxation chamber heart , call ventricle , collect pump blood . The use drug lead serious issue QT interval prolongation ( lengthen ) potentially serious arrhythmia ( abnormal heart beat ) , sudden death . Therefore , important study effect medication heart . The drug , Moxifloxacin , introduce control able compare effect , , CXA 101/tazobactam might participant 's heart.Moxifloxacin approve antibiotic commonly used treat common bacterial infection . Moxifloxacin know slightly increase electrical conduction participant 's heart .</detailed_description>
	<mesh_term>Tazobactam</mesh_term>
	<mesh_term>Penicillanic Acid</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Cephalosporins</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Healthy adult male and/or female , 1845 year age provide write Informed Consent . Body mass index ( BMI ) 1830 , inclusive . Medically healthy clinically significant abnormal screening result ( laboratory profile , medical history , ECGs , physical exam . Voluntarily consent participate study . Normal blood pressure ( &lt; 140 mmHg systolic &lt; 90 mmHg diastolic ) . Normal 12lead ECG , define : Consistent sinus rhythm No clinically significant conduction disorder PR interval 120 210 millisecond ( msec ) , inclusive Heart rate ( HR ) great equal 50 beat per minute ( bpm ) less equal 100 bpm QRS interval less equal 110 msec QT interval consistently analyze ( T wave amplitude 2 mm great , lack artifact [ noise ] excessive baseline wandering , without form bundle branch block ) . QTcF interval less equal 430 msec male less equal 450 msec female . Calculated creatinine clearance &gt; 80 mL/min . screen use CockcroftGault formula . If female , subject must negative serum pregnancy test screening agree either sexually inactive ( abstinent ) 14 day prior screen throughout study , use one follow acceptable birth control method : 1 . Intrauterine device ( IUD ) place least 2 month prior Day 1 study completion ; , 2 . Barrier method ( condom diaphragm ) spermicide least 14 day prior screen study completion ; 3 . Stable hormonal contraceptive ( medication , possible ) least 3 month prior Day 1 one month completion study ; 4 . Surgical sterilization ( vasectomy ) partner least 6 month prior Day 1 ; 5 . Naturally postmenopausal minimum 2 consecutive year prior Day 1 ; 6 . Surgically sterile ( bilateral tubal ligation surgery least 6 month prior Day 1 , hysterectomy , bilateral oophorectomy surgery least 2 month prior Day 1 ) . If male , subject agrees use medically acceptable contraceptive define : 1 . Abstain sexual intercourse study completion ; 2 . Use condom spermicide study completion ; 3 . Have vasectomy least 6 month prior Day 1 ; 4 . Have partner childbearing potential , study completion . History presence significant cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , psychiatric disease . History additional risk factor Torsade de Pointes ( e.g. , hypokalemia , family history long QT Syndrome , family history Short QT Syndrome , family history unexplainable early sudden death ) . History invasive cancer within past 5 year ( exclude nonmelanoma skin cancer ) . History sensitivity allergy quinolone class antibiotic , cephalosporin class antibiotic , betalactam class antibiotic . History presence alcoholism drug abuse within past 2 year . History hepatitis B , hepatitis C , Human Immunodeficiency Virus ( HIV ) . History clinically significant syncope . History clinically significant psychiatric illness would prevent subject provide valid Informed Consent Form ( ICF ) . Use tobacco product within previous 6 month . Donation blood within 45 day prior Study Day 1 . Plasma donation within 30 day prior Study Day 1 . Participation study investigational drug within 30 day prior baseline ECG . Participation another clinical trial within 30 day prior day checkin study . Female pregnant lactating . Has angina , uncontrolled hypertension , clinically significant cardiac arrhythmia , clinically significant cardiovascular abnormality . Positive laboratory result substance abuse , cotinine , alcohol . Taken prescription medication ( exception hormonal birth control medication hormone replacement therapy ) within 14 day ( 5 elimination halflives , whichever long ) admission unit ( Day 2 ) , take counter ( OTC ) medication , include topical medication , vitamin , herbal dietary supplements/remedies ( e.g. , Saint John 's Wort Milk Thistle ) , within 14 day admission , plan concomitant medication study ( except acetaminophen naproxen , need headache pain ) . In opinion Investigator , subject would able provide reliable study data available study followup .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>QT/QTc Intervals</keyword>
</DOC>